[ad_1]
People with the Johnson & Johnson coronavirus vaccine may be better off with a booster shot from Moderna or Pfizer-BioNTech. preliminary data From a federal clinical trial published Wednesday.
This finding is a mixed review case filed by the Food and Drug Administration Johnson and Johnson Approval of its booster could spark a heated debate about how and when additional vaccines will be offered to the 15 million Americans receiving a single dose.
The agency’s panel of vaccine advisors will meet on Thursday and Friday to vote on whether the agency should allow Moderna and Johnson & Johnson to make booster vaccines.
Despite questions raised by the new data about the strength of Johnson & Johnson’s boosters, some experts speculated that the agency would still clean up the vaccines, as the efficacy of the one-time vaccine is lower than that of two-dose mRNA vaccines that have been made. By Moderna and Pfizer-BioNTech. The wider public may also be awaiting authorizations, given the Biden administration’s push for boosters from all brands.
When the agency authorized a booster from Pfizer-BioNTech last month, “the mold was cast,” said John Moore, a virologist at Weill Cornell Medicine.
The Pfizer and Moderna vaccines are by far the most widely used vaccines in the United States. more than 170 million people Fully immunized with one or the other vaccine in the United States. When Johnson & Johnson was mandated in February, public health experts said “at once” option, especially in communities with poor access to healthcare. But when the popularity of the shot plummeted FDA later discontinued its use To investigate rare cases of blood clots.
For those who have the Johnson & Johnson vaccine, the timing of any brand’s support clearance is still unclear. The FDA panel is set to vote Friday on whether the agency should allow a second dose of the Johnson & Johnson vaccine; this scenario is one that the Centers for Disease Control and Prevention’s own vaccine advisory committee will discuss next week. If either agency believes an additional dose should be given, people can call them as early as next week.
It is unclear whether and how the FDA will allow a mix-and-match approach. The strategy will be discussed at Friday’s agency panel meeting, but there will be no vote. If regulators ultimately believe there is sufficient scientific support for the approach, they will need to update the authorization language for the Moderna and Pfizer-BioNTech vaccines to allow their use in people who originally bought Johnson & Johnson.
In a study led by the National Institutes of Health, researchers formed nine groups of about 50 people each. Each group received one of the three allowed vaccines followed by a booster. In three groups, volunteers received the same vaccine for a boost. In the other six, they switched to a different brand.
The researchers found that those who received the Johnson & Johnson vaccine followed by the Moderna booster had their antibody levels increased 76 times within 15 days, while those who received another dose of Johnson & Johnson only quadrupled over the same period. A Pfizer-BioNTech booster vaccine increased antibody levels 35-fold in Johnson & Johnson recipients.
The authors cautioned about the small size of the study and noted that they did not follow the volunteers long enough to detect rare side effects.
Scott Hensley, an immunologist at the University of Pennsylvania who was not involved in the new study, found the results compelling. However, he noted that the trial only looked at antibody levels, which alone is an insufficient measure of how well different combinations of vaccines will reduce Covid-19 infections and hospitalizations.
“At the end of the day, people with Johnson & Johnson should probably get an mRNA enhancer,” he said. “It’s just a matter of how much data does the FDA need before making this recommendation?”
“I wouldn’t want to be in their shoes,” he added.
Some scholars question how the federal government considers promoters of any brand, given the limited data provided not only by Johnson & Johnson but also by other companies.
An infectious disease specialist at Bellevue Hospital Center in New York City, Dr. “Some of us really want to see more data,” said Celine Gounder. “And then there are others who just want to get ahead on boosters.”
Earlier Wednesday, an FDA analysis questioned a key test used by the company, known as the psVNA test, and said it may have skewed the findings.
“The results appearing are likely to be due to the low sensitivity of the psVNA test used,” the FDA said in its report. The regulators also said they didn’t have enough time to independently review much of the raw data from the company’s trials.
Based on a large trial sponsored by the company, the FDA saw a potential improvement in protection from a Johnson & Johnson booster given two months after the first shot. Some scientists have argued that his vaccine should have been a two-dose shot from the start.
“Although not independently verified by the FDA from datasets, summaries of data suggest that a second dose administered approximately two months after the primary dose may provide benefit,” the agency said in its report.
Johnson & Johnson said in a statement that it looks forward to discussing the data on Friday, when panelists will also listen to a presentation on mixed and match work.
What to Know About Covid-19 Booster Shots
FDA authorized booster shots For a selected group of people who have received their second dose of the Pfizer-BioNTech vaccine at least six months ago. This group includes: Pfizer recipients aged 65 and over or living in long-term care facilities; adults at high risk of serious Covid-19 due to an underlying medical condition; healthcare workers and others whose jobs put them at risk. with people weakened immune systems they are eligible to receive a third dose of Pfizer or Moderna four weeks after the second shot.
Regulators have not yet allowed booster vaccines for recipients of Moderna and Johnson & Johnson vaccines, but FDA panel scheduled to meet To weigh booster vaccines for adult recipients of Moderna and Johnson & Johnson vaccines.
The CDC said conditions that qualify a person for a booster shot include: hypertension and heart disease; diabetes or obesity; cancer or blood diseases; weakened immune system; chronic lung, kidney, or liver disease; dementia and some disabilities. Pregnant women and current and former smokers are also eligible.
The FDA has allowed boosters for workers whose jobs put them at risk of exposure to potentially infectious humans. The CDC says the group includes: emergency health workers; education workers; food and agricultural workers; manufacturing workers; correction workers; US Postal Service employees; public transport workers; grocery workers.
Not recommended. For now, Pfizer vaccine recipients are advised to receive the Pfizer booster vaccine, and Moderna and Johnson & Johnson recipients are advised to wait until booster doses from these manufacturers are approved.
Yeah. The CDC says the Covid vaccine can be administered regardless of the timing of other vaccines, and many pharmacy sites allow people to schedule a flu shot at the same time as a booster dose.
Jason L. Schwartz, associate professor of health policy at the Yale School of Public Health, said the FDA’s discussion this week about the Johnson & Johnson vaccine has big implications for the vaccine’s future in the United States. He said the vaccine is already unlikely to gain greater acceptance in the country in the long run. And if the FDA eventually recommends a different vaccine to Johnson & Johnson recipients with a booster vaccine, “it’s hard to see what will lead people to J.&J.,” he added. vaccine.”
FDA has already authorized an additional shot Pfizer-BioNTech vaccine For people ages 18 to 65 who are older than 65 or have underlying health conditions or work exposures that put them at higher risk. Moderna’s application, which will be discussed on Thursday, may also gain authorization, Despite limited evidence that it provides protection It decreases with respect to the first two dosing regimens of Moderna.
On Wednesday, regulators wrote that a single shot of the Johnson & Johnson vaccine “still protects against serious Covid disease and death in the United States.” However, they said the highest estimates of protection, including severe Covid, were “consistently lower than the highest estimates of effectiveness” for the Moderna and Pfizer-BioNTech shots.
A clinical trial, a dose of J.&.J. had an activity rate 66 percent Against moderate to severe Covid worldwide and 74 percent in the United States. Its effectiveness against severe or critical illness was 85 percent stronger worldwide.
In a booster submission, Johnson & Johnson included the results of another large-scale study that began in November 2020, where they gave half of their volunteers a second dose two months after the first. The other half received a placebo.
In August, the company announced that activity had risen to 94 percent during the portion of the trial that took place in the United States. But in its report, the FDA focused on results worldwide, where the increase was more modest, rising to 75 percent.
Dr. Hensley cautioned that the efficacy estimates from trials have quite a wide uncertainty. “What that tells you is that small changes in activity here can be down to luck,” he said.
Against severe to critical Covid disease, the two shots had 100 percent effectiveness. But regulators warned that there is little data from this trial on the Delta variant, which currently causes the vast majority of infections in the United States, in the analysis published Wednesday.
The emphasis on boosting Johnson & Johnson’s vaccine with a second shot “reflects that our supportive conversation in recent weeks has shifted only to preventing serious cases, hospitalizations and deaths. That’s down to how we prevent infections, period,” said Dr. Schwartz. “J.&J. was lagging behind all along.”
In August, the Biden administration’s top health officials said when they announced plans to begin administering booster vaccines to Moderna and Pfizer-BioNTech recipients in September, they thought those who received Johnson & Johnson’s vaccine would also need a shot, but more data would be needed.
Dr. Schwartz said this announcement “creates unreasonable expectations” for those who get the Johnson & Johnson vaccine, adding that “the J.&J. conversation is much more confusing.”
Sharon LaFraniere contributed to the news from Washington.
[ad_2]
Source link